CREATE Medicines Doses First Patient in Frontline HCC Trial Evaluating MT-303, an In Vivo CAR Therapy, in Combination with Standard-of-Care Immunotherapy

CREATE Medicines Inc., a clinical-stage biotechnology company pioneering in vivo multi-immune programming, today announced ...
PharmiWeb

Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)

In the MZL cohort of TRANSCEND FL, Breyanzi delivered deep and durable responses in 95.5% of patients while demonstrating a ...
Pharmabiz

Bristol Myers Squibb advances lymphoma research with new targeted protein degradation and cell therapy data at ASH 2025

Consistently high efficacy was seen across subgroups with ORR of 96%-100% and three-year ongoing response rates of 60%-83%, including in patients with high-risk characteristics (progression of disease ...

Cogent Biosciences, Inc. (COGT) Discusses Full SUMMIT and Positive APEX Trial Results in Systemic Mastocytosis at ASH Conference Transcript

Discusses Full SUMMIT and Positive APEX Trial Results in Systemic Mastocytosis at ASH Conference December 8, 2025 8:00 ...
PharmiWeb

EpilepsyGTx Raises $33 Million Series A to Develop Single Dose Gene Therapy for Focal Refractory Epilepsy

Investment from XGEN Venture, British Business Bank, and a global biopharmaceutical company will support first-in-human Phase ...

Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next ...

FT819 continues to demonstrate meaningful decrease in disease and favorable safety profile with twelve systemic lupus erythematosus (SLE) ...

Gen Z & Millennials Are Changing Mental Health in 2025; Here’s Why It Matters to You

Gen Z and Millennials are reshaping the mental health narrative in 2025 by encouraging open conversations, prioritizing ...

Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of ...

Data show deep, durable responses in the 50 million cell dose level cohort; initial data suggest substantial early improvement in three patients ...

5 common causes of muscle mass loss (& how to prevent them)

Loss of muscle mass, also called muscle wasting or atrophy, can happen gradually as part of getting older or more suddenly ...
Medindia

CLINUVEL Expands Singapore RD&I Centre to Pioneer Next-generation Peptide Therapies

VALLAURIX Research, Development & Innovation Centre to expand its existing facilities and capabilities core focus on accelerating development of liquid long-acting drug delivery platforms existing ...